<div id="readability-page-1"><article><ul type="disc"><li>FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut Extract</li><li>Company has signed an option agreement with Florida State University (FSU) to license a capsule formulation, expanding on its recent exercise of a license option for large-scale production</li></ul> WASHINGTON, March 18, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it submitted a New Dietary Ingredient Notification (NDIN) to the U.S. Food and Drug Administration (FDA) for Australian Chestnut Extract on March 11, 2026. FDA has until May 25, 2026, to object to the notification, after which the Company will be free to market its planned dietary supplement containing Australian Chestnut Extract. The Company has also signed an option agreement to license Florida State University’s (FSU) ownership rights related to new capsule formulation methods for Australian Chestnut Extract, which FSU jointly owns with the Company. This expands on the Company’s January 2026 exercise of a license option with FSU for exclusive rights to large-scale purification of Castanospermine for non-prescription uses. <div>Australian Chestnut Extract is derived from the seeds of Castanospermum australe (commonly known as the Australian Chestnut, the Moreton Bay Chestnut, and the Black Bean Tree). The dominant molecular constituent of Australian Chestnut Extract is castanospermine.According to recent scientific literature, at low doses, castanospermine modulates carbohydrate metabolism, altering glycogen, glucose levels, and other clinical markers. In animal models, high doses have been shown to impact disease outcomes in several therapeutic areas through immunomodulation.</div> Castanospermine is also a metabolite of celgosivir, a product evaluated in clinical trials in more than 500 patients against HIV and Hepatitis C, but which is no longer in commercial development for those indications. That safety record suggests castanospermine is safe at achievable doses in humans and is active against the same pharmacological targets as in animal studies. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of Its lead product, ARAKODA® (tafenoquine) in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Australian Chestnut or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward- looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 27, 2025 and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contact: Sheila A. Burke SheilaBurke-consultant@60degreespharma.com (484) 667-6330 Investor Contact: Patrick Gaynes patrickgaynes@60degreespharma.com <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZM05ERTBOU00zTkRrd09USTVJekl4T0RJek16Zz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZM05ERTBOU00zTkRrd09USTVJekl4T0RJek16Zz0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjhhZDg5NDMtNzA5MS00NDE1LTliYTMtZTM3ZmM5NTFlOTk1LTExOTM5MDctMjAyNi0wMy0xOC1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjhhZDg5NDMtNzA5MS00NDE1LTliYTMtZTM3ZmM5NTFlOTk1LTExOTM5MDctMjAyNi0wMy0xOC1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png"/></article></div>

SXTPW

60 Degrees Pharmaceuticals, Inc. has submitted a New Dietary Ingredient Notification (NDIN) to the FDA for Australian Chestnut Extract, with the FDA having until May 25, 2026, to object. The company has also signed an option agreement with Florida State University to license a capsule formulation. Australian Chestnut Extract, derived from Castanospermum australe, shows potential in modulating carbohydrate metabolism and impacting disease outcomes in animal models. The company specializes in developing medicines for vector-borne diseases and has previously achieved FDA approval for its lead product, ARAKODA®.

StockTitan

Proshares Ultra Nasdaq Biotech

60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM)

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

60 Degrees Pharmaceuticals

iShares US Pharma

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VG Health

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract | SXTP Stock News